What XcellGene Does

Our technique produces LT-HSC from the peripheral blood of patients, allowing for the generation of cells that can self-renew indefinitely for months or even years.

This process takes less than 24 hours and can be implemented in hospitals at minimal expense, making advanced therapies accessible to more patients.

Our LT-HSC generation is suitable even for elderly patients, including those over 70, expanding the range of individuals who can benefit from these therapies.

• Cardiovascular Disease: For heart failures and coronary infarction with no alternative treatment. LT-HSC may be able to repair damaged heart muscle cells and its inflammatory environment
• Cancer Treatment: By creating cancer-fighting HSC cells known as CAR-HSC, similar to CAR-T cells, providing innovative long term solution and a less expensive treatment options.
• Gene Edit and Reprogramming: LT-HSC used for gene edit and reprogramming will have long lasting efficacy.

• Revolutionize hematopoietic stem cell transplants, offering new possibilities for treatment of patients who are unable to perform a transplant due to inadequacy of self-generated hematopoietic stem cells.
• Hematopoietic Stem Cell Transplant (HSCT): LT-HSC may be able to augment current FDA approved HSCT for AML, ALL, lymphomas and multiple myelomas in patients who are unable to generate enough autologous hematopoietic stem cells (HSC) or may have cancer stem cells in their own HSC.

LT-HSC has never been successfully generated ex vivo by anyone else, positioning us at the forefront of hematopoietic stem cell research and therapy. Some of which will likely include the unlimited potential to augment CRISPR/cas 9 sgRNA guided in combination of AAV transduced template of HDR cDNA.